The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
 
Matthew Reilley
No Relationships to Disclose
 
Ann Marie Bailey
No Relationships to Disclose
 
Vivek Subbiah
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Biotherapeutics (Inst); Bioxell Pharma (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Multivir (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
Filip Janku
Consulting or Advisory Role - Deciphera; Trovagene
Research Funding - Biocartis; BioMed Valley Discoveries; Foundation Medicine; Novartis; Roche; Trovagene
Other Relationship - Bio-Rad
 
Aung Naing
Research Funding - Amplimmune (Inst); ARMO BioSciences (Inst); Atterocor (Inst); Baxter (I); Baxter (I); EMD Serono (Inst); Healios (Inst); Healios (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Novartis (Inst); Regeneron (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Celgene; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Kolltan Pharmaceuticals; MedImmune; Millennium; Novartis; Regeneron; Strategia Therapeutics; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - EMD Serono; Millennium; Sarah Cannon Research Institute
 
Daniel D. Karp
No Relationships to Disclose
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); EMD Serono (Inst); Foundation Medicine (Inst); ONYX (Inst)
 
Siqing Fu
No Relationships to Disclose
 
Ralph Zinner
No Relationships to Disclose
 
JoAnn Lim
No Relationships to Disclose
 
Stacie A. Bean
No Relationships to Disclose
 
Allison Bass
No Relationships to Disclose
 
Sandra Montez
No Relationships to Disclose
 
Luis M Vence
No Relationships to Disclose
 
Padmanee Sharma
Leadership - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Neon Therapeutics (I); SAB-Pharma; SAB-Pharma (I)
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline
Research Funding - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
James Patrick Allison
Patents, Royalties, Other Intellectual Property - Inventor of a patent held by the University of California, Berkeley, and licensed to Bristol Meyers-Squibb; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
David S. Hong
No Relationships to Disclose